J Korean Ophthalmol Soc.  2005 Dec;46(12):2071-2080.

Changes in Retinal Neuronal Population in DBA/2J Mice with Topical Intraocular Pressure Lowering Drugs

Affiliations
  • 1Department of Ophthalmology, College of Medicine, The Catholic University of Korea, Korea. jimoon@catholic.ac.kr
  • 2Department of Anatomy, Seoul, Korea.

Abstract

PURPOSE
The DBA/2J (D2) mouse is a transgenic mouse with pigmentary glaucoma. In a previous study, we found a reduction of inner retinal thickness in D2 mice. We attempted to discover the effect of eye drops on the retina of D2 mice. METHODS: Ten-month-old D2 mouse eyes were treated with Timoptic XE(R), Cosopt(R), and Xalacom(R) eye drops for a 1-month period. Immunohistochemical staining was performed on the mouse eye sections for analysis.
RESULTS
In the control group, GABA and OPN immunoreactivity were markedly decreased and NOS immunoreactivity was increased. In all experimental group, GABA and OPN immunoreactivity were increased, and OPN immunoreactivity was markedly increased especially in the Cosopt(R) group. NOS immunoreactivity was decreased in all experimental groups. There was no difference in glycine immunoreactivity between the control and experimental groups.
CONCLUSIONS
Combination anti-glaucoma eye-drops to the D2 mouse changed the retinal neuronal population and these drugs might play an important role in the mechanisms of retinal neuronal death; potential strategies for neuroprotection should therefore be evaluated.

Keyword

Amacrine cell; Anti-glaucoma drug; DBA/2J mice; Ganglion cell; Nitrergic cell

MeSH Terms

Amacrine Cells
Animals
gamma-Aminobutyric Acid
Glaucoma, Open-Angle
Glycine
Intraocular Pressure*
Mice*
Mice, Transgenic
Ophthalmic Solutions
Retina
Retinal Neurons*
Retinaldehyde*
Timolol
Glycine
Ophthalmic Solutions
Retinaldehyde
Timolol
gamma-Aminobutyric Acid
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr